Company ProfilePremium

Amradeep Industries Limited

Company Profile Analysis

Tickers: AMARDEE.NS, 531681.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Amradeep Industries Limited - Company showcase

Year Founded & Workforce

1984

Amradeep Industries Limited logo

Amradeep Industries Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Amradeep Industries Limited Overview

Amerise Biosciences Limited is a 42-year-old BSE-listed Gujarat company that began life as Amstar Laminates. It drifted through laminates, commodity trading and castor-seed trading as Amradeep Industries, and was renamed in 2021 to signal a move into "biosciences". In practice the listed entity has had no meaningful operations for most of the past decade. Revenue was zero in most years. The one exception was a single INR 9.58 crore trading year in FY2026's predecessor period, FY2022. The balance sheet holds about INR 7.4 crore of total assets, mostly investments and other current assets, with no debt and no fixed assets. Net worth of about INR 5.4 crore roughly matches the market value. The company has no identified promoter, a retail-dominated register of about 33,000 holders, and frequent changes to its key managerial personnel and website domains. Some aggregators link it to Amerise Pharmaceuticals Pvt Ltd, an Ahmedabad pharmaceutical development firm, but no filed corporate relationship has been verified. The investment case rests on corporate action, not on operations.


What the company does today. On the evidence available, the listed company does not run an identifiable operating business:

  • Tickertape describes it as currently inactive with no revenue generation.

  • Kotak Neo's profile, drawing on the company's disclosures, says that in FY2025 the company carried out no business activities because of a "financial crisis".

  • Screener's legacy profile describes it as non-operational for several years.

Company's own description. Exchange and broker profiles, which derive from company filings, describe the history as follows. The company was incorporated in 1984 as Amstar Laminates, described as a maker of construction and agricultural equipment. It was renamed Amradeep/Amardeep Industries on 29 October 2002 and Amerise Biosciences in 2021. It was originally engaged in commodity trading and added castor-seed trading in FY2007.

The 2009–10 annual report on BSE refers to the castor-seed trading environment in Gujarat, which is consistent with this history. The description of "construction and agricultural equipment" manufacturing is inconsistent with the "Laminates" name and with Screener's description of decorative boards and laminate sheets. Both versions circulate in aggregator databases, and the discrepancy is unresolved in the sources reviewed.

That is the website of Amerise Pharmaceuticals Pvt Ltd, a private company established in 2018. It focuses on NDA, 505(b)(2) and complex formulations (injectables, ophthalmics, oral dosage forms) and has offices in Cranbury (New Jersey, USA), Buckshaw Village (Lancashire, UK) and Bodakdev (Ahmedabad, India).

The listed company reports no subsidiaries in available data, and its balance sheet carries no fixed assets, laboratories or R&D spend. It may be a naming coincidence or an aggregator misattribution, or it may signal an intended but undisclosed relationship.

Business model and revenue model. No recurring revenue model exists.

Screener's quarterly data show small "sales" in each quarter of FY2026 (0.06, 0.07, 0.04 and 0.08), which sum to about INR 0.25 crore. The annual statement instead books about INR 0.26 crore as other income and zero as sales. This is a classification discrepancy between quarterly and annual presentation. Either way, the income most likely reflects interest or financing income on loans and advances, not trading.

Value-chain position, customers and end-markets. Not applicable or not publicly disclosed. Data vendors classify the company in very different industries:

  • Plastic Products – Industrial (Screener, MarketsMojo)

  • Finance – Investment (StockEdge, MoneyWorks4Me)

  • Other Agricultural Products (Research360)

  • Pharmaceuticals (Emkay)

  • Blank-check company (MarketScreener)

This spread is itself diagnostic of an entity without a defined business.

Independent characterisation. Amerise Biosciences is best described as a listed shell with a small treasury of investments and loans. It is funded entirely by legacy equity of INR 6.61 crore, with accumulated losses of about INR 1.2 crore. Its main economic asset is its BSE listing and a large, fragmented retail shareholder base. The FY2022 burst of INR 9.58 crore of trading revenue coincided with an 84-fold rise in shareholder count, and the 2021 rename to "biosciences" came without any disclosed pharmaceutical assets. Taken together, these show a listed vehicle whose narrative has shifted without the operations to support it.

Strategy

Stated strategy. No corporate strategy statement, investor presentation, investor day or earnings call exists in public sources. The 2021 renaming to "Amerise Biosciences" is the only implicit strategic signal, pointing to biosciences or pharmaceuticals. In five years since then, the company has disclosed no supporting initiative: no acquisition, licence, capital raise, plant, R&D spend or regulatory filing.

Initiatives in the last 24 months (Oct 2024 – Oct 2026).

Transformation programmes, partnerships, ESG commitments, cost programmes: none disclosed. Medium-term financial targets or guidance: none issued.

Products & Services

Pricing models, flagship offerings, launch years: not publicly disclosed or not applicable. The listed company has no named brands, platforms or active product lines. The patents and applications that Amerise Pharmaceuticals' website lists belong to that private company and are not attributable to the listed entity on current evidence. Examples include an anti-vertigo compound (WO2022091118) and a stable non-steroidal antiandrogen composition.

Product Portfolio

SegmentProduct / serviceDescriptionStatusSource

Single segment

Decorative boards and laminate sheets (historical)

Laminates manufacturing and trading under the Amstar Laminates identity

Discontinued; non-operational for years

Screener legacy profile

Single segment

Commodity trading (historical)

General commodity trading

Discontinued or dormant

Company profiles

Single segment

Castor-seed trading (historical, FY2007 onward)

Trading in Gujarat-grown castor seeds

Dormant; no revenue since FY2022 except trivial amounts

FY2010 annual report; profiles

Single segment

Construction and agricultural equipment (as described in profiles)

Profiles say the company was set up to make such equipment

No evidence of production in reviewed financials (zero fixed assets since at least FY2015)

Company profiles

Single segment

"Biosciences" / pharmaceutical development

Implied by the 2021 rename. Screener links the description to Amerise Pharmaceuticals Pvt Ltd (NDA, 505(b)(2), complex injectables, ophthalmics, oral forms)

—

Screener; amerisepharma.com

Single segment

Financing / treasury income

Other income of INR 0.19 crore (FY2025) and INR 0.26 crore (FY2026), possibly interest on loans and advances

Current, sole income source

Screener

Financial Narrative

Source for all tables: Screener.in standalone financials compiled from BSE filings, FY2022–FY2026, INR crore unless stated. Ratios marked "derived" are arithmetic computations from these figures, not vendor-reported values.

Income statement

Gross profit is not reported separately; Screener aggregates cost of goods into total expenses. Diluted EPS equals basic EPS, since no dilutive instruments are disclosed.

Margins

Blank cells mean not meaningful (zero revenue denominator). The revenue CAGR from FY2022 to FY2026 is not computable because FY2026 revenue was zero. Screener reports 10-year, 5-year and 3-year sales CAGRs as blank and TTM sales growth as –24%.

Balance sheet

Additional notes on the balance sheet:

Cash and equivalents: Not separately disclosed in reviewed aggregates for FY2022–FY2025. Zerodha's data show net debt of –INR 0.59 crore as of March 2026, which implies cash of about INR 0.59 crore with zero debt. This is consistent with Screener's FY2026 net cash flow of +INR 0.57 crore.

Short- and long-term debt split: Not disclosed. The FY2022–FY2023 borrowings of INR 0.08–0.09 crore were repaid in FY2024.

Working capital: Screener reports working-capital days of –1.91 (FY2022), –1,460 (FY2023) and –182.5 (FY2024); FY2025–FY2026 are not computable on zero revenue.

Ratios

The following ratios are not meaningful or not computable:

ROIC: not separately computable; it approximates ROCE, since the company has no debt.

Interest coverage: interest expense is zero. Screener's automated flag of "low interest coverage" is a mechanical artefact.

Net debt/EBITDA: negative EBITDA and net cash.

Current ratio: the classification of other assets and liabilities between current and non-current is not disclosed. A crude derived proxy of other assets divided by other liabilities gives about 1.8x for FY2026.

Commentary on trends, inflections and drivers

FY2022 is the sole operating inflection. Revenue of INR 9.58 crore against expenses of INR 9.03 crore gave a 5.7% margin, the pattern of pass-through trading. Year-end other liabilities of INR 6.27 crore and other assets of INR 7.30 crore swelled the balance sheet to INR 11.99 crore. Both unwound within twelve months, and FY2023 revenue was INR 0.01 crore. The episode coincided with the rename to Amerise Biosciences and an 84-fold rise in the shareholder count, from 175 to 14,701. The counterparties and the nature of the traded goods are not disclosed in reviewed sources. That opacity is a key diligence point.

FY2023–FY2024 were dormant years. The company ran annual cash burn of about INR 0.13–0.17 crore to cover listing, audit, RTA and compliance costs, and reserves declined slowly.

FY2025–FY2026 brought a shift to treasury income. The P&L turned marginally positive (INR 0.01 crore and INR 0.02 crore) only because other income of INR 0.19 crore and INR 0.26 crore covered running costs. The cash-flow pattern shows large offsetting movements: +3.07 operating and –3.07 investing in FY2025, then –1.06 operating and +1.63 investing in FY2026. Alongside the rise and fall in other liabilities (INR 3.08 crore in FY2025, INR 2.03 crore in FY2026), this is consistent with funds received and lent or invested on behalf of others, such as inter-corporate deposits or advances. The quality of those receivables and investments is undisclosed and is the main balance-sheet risk.

Q1 FY2027 (June 2026 quarter) reverted to a pure loss of INR 0.08 crore, with zero income and expenses of INR 0.08 crore. This shows that the FY2026 profit depended on treasury income that has not recurred.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Revenue by Segment (%)

SegmentFY2024FY2025FY2026

Revenue from operations, single segment (INR Cr)

0.040.000.00

Other income (INR Cr)

0.000.190.26

Pre-tax profit (INR Cr)

-0.150.010.02

Share of total revenue from operations (%)

10000

Revenue by Segment

MetricJun-2023Sep-2023Dec-2023Mar-2024Jun-2024Sep-2024Dec-2024Mar-2025Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Sales (INR Cr)

0.000.000.000.040.000.000.000.190.060.070.040.080.00

Expenses (INR Cr)

0.070.040.060.020.050.030.020.080.070.110.030.020.08

Net profit (INR Cr)

-0.07-0.04-0.060.02-0.05-0.03-0.020.11-0.01-0.040.010.06-0.08

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

9.580.010.040.000.00

Other income (INR Cr)

0.000.000.000.190.26

Total expenses (INR Cr)

9.030.130.190.180.24

Operating profit / EBITDA excl. other income (INR Cr)

0.55-0.12-0.15-0.18-0.24

Depreciation (INR Cr)

0.000.000.000.000.00

Interest (INR Cr)

0.000.000.000.000.00

Pre-tax income (INR Cr)

0.55-0.12-0.150.010.02

Tax (INR Cr)

0.000.000.000.000.00

Net income (INR Cr)

0.55-0.12-0.150.010.02

EPS basic (INR)

0.08-0.02-0.020.000.00

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024

Operating margin (%)

5.74-1,200-375

Net margin (%, derived)

5.74-1,200-375

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

6.616.616.616.616.61

Reserves and surplus (INR Cr)

-0.97-1.09-1.23-1.23-1.21

Total equity (INR Cr, derived)

5.645.525.385.385.40

Borrowings, total (INR Cr)

0.080.090.000.000.00

Other liabilities (INR Cr)

6.270.040.013.082.03

Total assets (INR Cr)

11.995.655.398.467.43

Fixed assets incl. CWIP (INR Cr)

0.000.000.000.000.00

Investments (INR Cr)

4.694.572.272.383.77

Other assets (INR Cr)

7.301.083.126.083.66

Goodwill and intangibles (INR Cr)

00000

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operations (INR Cr)

0.06-0.13-0.173.07-1.06

Cash from investing (INR Cr)

-0.150.130.27-3.071.63

Cash from financing (INR Cr)

0.080.01-0.090.000.00

Net cash flow (INR Cr)

-0.010.000.010.000.57

Capex (INR Cr)

00000

Free cash flow (INR Cr)

0.06-0.13-0.173.07-1.06

Dividends paid (INR Cr)

00000

Buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROCE (%, Screener)

10.18-2.12-2.730.190.37

ROE on average equity (%, derived)

10.3-2.2-2.80.190.37

ROA on year-end assets (%, derived)

4.6-2.1-2.80.10.3

Debt to equity (x, derived)

0.010.02000

Asset turnover (x, derived on year-end assets)

0.800.000.0100

Cash conversion cycle (days, Screener)

236.9800——

Revenue by Region

RegionFY2024FY2025FY2026

Total revenue from operations, all geographies (INR Cr)

0.040.000.00

Valuation Snapshot

MetricValueSource / date

Current price (INR)

0.81

Screener, 19 Oct 2026

52-week high / low (INR)

1.03 / 0.50

Screener / IIFL, 2026

1-year price change (%)

47

Screener stock-price CAGR, Oct 2026

3-year price CAGR (%)

12

Screener, Oct 2026

5-year price CAGR (%)

-12

Screener, Oct 2026

10-year price CAGR (%)

-4

Screener, Oct 2026

Capital Markets

MetricFY2026

Share price near fiscal year end (INR; Mar-2024 n/a, Mar-2025 n/a, Mar-2026 27-Mar close)

0.62

Valuation Multiples

MultipleAmerise BiosciencesComment

P/B

0.99x

Screener

EV (INR Cr, derived)

About 4.76

Market cap 5.35 less March 2026 net cash of 0.59

EV/Sales (TTM, derived)

About 25x

On TTM "sales" of INR 0.19 crore (quarterly series)

Peer P/B (BAMPSL Securities, Equitymaster)

About 0.9–1.0x

Comparable

Analyst Conclusions

Management guidance: none issued. Consensus growth expectations: none, as there is no coverage.

Bull case

  1. Clean shell at book value. A debt-free listed vehicle trading at about 1x book (INR 5.4 crore) with a 33,000-holder register is a low-cost listing route. Any reverse merger or business injection would likely re-rate it well above book.

  2. Signs of a shareholder group building a position. SAST Reg. 29(1)/29(2) disclosures by Snehjeev Ventures & PACs indicate a group crossing 5% and adding to its stake, a common precursor to an open offer or change of control.

  3. Governance reset. A new Company Secretary (Apr 2026) and WTD & CFO (Sep 2026) could herald fuller disclosure and a defined strategy, potentially including the long-signalled biosciences pivot.

Bear case

  1. No business, five years after the "biosciences" rename. Zero fixed assets, zero R&D, zero annual revenue in FY2025–FY2026, and an admitted absence of business activity in FY2025.

  2. Book value of uncertain quality. About INR 7.4 crore of investments and other assets is unitemised. The two-way cash-flow swings (±INR 3 crore in FY2025) and the swelling and contraction of other liabilities look like pass-through financing, so book value could be impaired.

  3. Surveillance and governance red flags. GSM/ASM designation, 0% promoter holding, three KMP changes in eight months, repeated domain changes, and the pattern of a FY2022 revenue spike alongside an 84-fold rise in shareholder count all point to elevated regulatory and investor-protection risk.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Q2 FY2027 results (September quarter)By mid-Nov 2026 (trading window closed from 1 Oct 2026)Whether treasury income resumes or losses continue
Itemised FY2026 annual report notes (investments, loans, related parties, contingent liabilities)Already filed; needs reviewAsset quality is the core valuation question
Any Reg. 30 disclosure of business acquisition, preferential issue or scheme of arrangementUnscheduledWould define the post-shell strategy
SAST filings / open offer by Snehjeev Ventures & PACs or othersUnscheduledA change in control would be the main re-rating trigger
GSM/ASM status changesOngoingLiquidity and suspension risk
Disclosure of any relationship with Amerise Pharmaceuticals Pvt LtdUnscheduledWould validate or refute the biosciences narrative
Further KMP or board changes; website stabilityOngoingGovernance signal

Concluding analyst verdict

Amerise Biosciences Limited, the former Amradeep Industries Limited, should not be analysed as an operating company. It is a 1984-vintage Gujarat entity that has moved through laminates, commodity trading and castor seeds. It took a "biosciences" name in 2021 but has not acquired any biosciences assets, revenue, staff or R&D in the five years since. Its financial statements describe a dormant shell:

  • equity of about INR 5.4 crore built on INR 6.61 crore of legacy capital less accumulated losses

  • zero debt and zero fixed assets

  • annual running costs of INR 0.2 crore, offset in FY2025–FY2026 by treasury-type income that did not recur in Q1 FY2027

The single year of real activity, FY2022's INR 9.58 crore of thin-margin trading, coincided with the rename and an extraordinary influx of retail shareholders. Its counterparties remain undisclosed.

The valuation is anchored to book: at INR 0.81 the market cap of INR 5.35 crore is about 0.99x net worth. Downside therefore depends on the quality of roughly INR 7.4 crore of investments and other assets that public sources do not itemise. Upside depends entirely on corporate action, such as a change of control, a reverse merger or a real business injection. The SAST disclosures by Snehjeev Ventures & PACs and the 2026 KMP reconstitution are the only tangible hints that such action may be in prospect, and neither confirms it.

Governance is the binding constraint. The company has no promoter, is under BSE GSM/ASM surveillance, has seen rapid KMP turnover, and has changed its website domain repeatedly.

Verdict: Not investable on fundamentals; speculative special-situation only. The stock warrants monitoring for Regulation 30 disclosures of corporate action, but any position is effectively a bet on an unannounced transaction by unidentified parties. Prudent investors should first obtain the full FY2026 annual report notes, particularly on investments, loans, related-party transactions and contingent liabilities.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenurePrior / other rolesSource

Albert Hines

Whole-time Director & CFO

Appointed at AGM, 24 Sep 2026

—

BSE AGM outcome (Screener summary)

Kelash Bunkar

Independent Non-Executive Director

Start date not disclosed

—

Blinkx board listing

Dineshkumar Tribhovanbhai Rathod

Former Whole-time Director, Director (Finance) & CFO

2021 – 2 Feb 2026

Independent Non-Executive Director at Interface Financial Services Ltd, Amraworld Agrico Ltd and Suncare Traders Ltd (all from 22 Nov 2021)

MarketScreener; Blinkx

Company Secretary & Compliance Officer

—

Changed on 15 Apr 2026 (resignation plus new appointment)

Names not disclosed in reviewed sources

Emkay / Dion Global

Mahendra Ganatra (historical)

Director

Retired by rotation at the 25th AGM (FY2010) and eligible for reappointment

—

BSE annual report 2009–10

“—” = not publicly disclosed.

Major Shareholders

Holder categorySep 2026

Promoter & promoter group (%)

0.00

Public (%)

100.00

Number of shareholders

33,026

Metric

FY2021

Number of shareholders (count, March)

175

Competitive Landscape

Peer Comparison FY2024

MetricAmerise Biosciences (FY2024)BAMPSL Securities (FY2024)Century Twenty (FY2023)

Net sales (INR Mn)

08417

Shares outstanding (M)

66.0734.042.07

Book value per share (INR)

0.811.210.2

Average market cap (INR Mn)

51369219

R&D intensity (%)

000

Recent Developments

The company publishes no press releases, so this register is drawn from BSE filings as indexed by aggregators.

There were no contract wins, product launches, guidance revisions, litigation, layoffs or restructurings in the period.

Company Snapshot

1984

Founded

Gandhinagar, India

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet. Borrowings fell to zero in FY2024 (from INR 0.09 crore in FY2023), and net debt was –INR 0.59 crore at March 2026 (Screener; Zerodha).
  • Positive net worth. Equity of INR 5.40 crore (FY2026) against market capitalisation of INR 5.35 crore gives a P/B of about 0.99x (Screener, Oct 2026).
  • Low fixed cost base. Annual expenses of INR 0.18–0.24 crore (FY2025–FY2026) mean very slow erosion of net worth.
  • Long listing history. The company has been BSE-listed for three decades, an asset for any reverse-merger candidate.
  • Large shareholder base. 33,026 holders (Sep 2026) provide a ready float and comfortably meet minimum public shareholding norms.
  • Treasury income has covered costs. Other income of INR 0.19 crore (FY2025) and INR 0.26 crore (FY2026) kept the P&L marginally positive in both years.

Weaknesses

  • No operating business. Revenue was zero in FY2025 and FY2026 per annual statements, and the company reported no business activity in FY2025 (Kotak Neo).
  • Name-substance mismatch. "Biosciences" since 2021 with zero fixed assets and zero R&D (Screener FY2015–FY2026).
  • No promoter. 0% promoter holding (Screener, Sep 2026) means no controlling party is accountable for strategy.
  • Opaque asset quality. Investments of INR 3.77 crore and other assets of INR 3.66 crore (FY2026) are not itemised in reviewed sources.
  • Governance churn. CFO exit (Feb 2026), CS change (Apr 2026) and new WTD & CFO (Sep 2026), plus website domain changes (Oct 2025, Oct 2026).
  • Accumulated losses. Reserves of –INR 1.21 crore (FY2026). The 10-year ROE is about –2% (Screener).

Opportunities

  • Reverse-merger or asset injection. A debt-free shell valued at book could be used to list an operating business. The SAST filings by Snehjeev Ventures & PACs show active accumulation by a shareholder group.
  • Formalising a pharma business. If an Amerise-branded pharma business were injected, the 505(b)(2) and complex-injectables positioning described on amerisepharma.com would transform the profile.
  • Recovery of investments. The FY2026 investing inflow of INR 1.63 crore shows assets can be realised.
  • Exit from surveillance frameworks. Leaving GSM/ASM after compliance and stable trading would improve liquidity.
  • New finance leadership. The September 2026 appointment of a WTD & CFO may precede a cleaner disclosure regime.
  • GIFT City address. Proximity to an IFSC ecosystem, though no IFSC licence is disclosed.

Threats

  • Regulatory action. Shell-type companies under GSM/ASM face heightened SEBI and BSE scrutiny, with potential trading suspension.
  • Net-worth erosion. Q1 FY2027 showed a loss of INR 0.08 crore with zero income. At FY2027's run-rate, losses resume.
  • Recoverability risk. If loans or advances behind other assets are impaired, book value (INR 0.82 per share) could fall sharply.
  • Illiquidity and price volatility. The one-year swing ran from –52% (Dec 2025) to +47% (Oct 2026).
  • Retail investor harm. A rapid shareholder build-up (175 to 36,595 holders between FY2021 and FY2025) in a non-operating company is a pattern regulators associate with speculative trading.
  • Misattribution risk. Investors may wrongly impute the private Amerise Pharmaceuticals' assets to the listed shell.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
19 May 2025Board meeting: audited FY2025 results; March 2025 quarter profit after tax of INR 10.60 lakhMarginal profit came entirely from income booked as sales/other income; FY2025 net profit INR 0.01 crore
May 2025FY2025 results show no business activity in the year "due to financial crisis" (company-derived profile)Confirms dormancy
24 Jul 2025Board meeting: Q1 FY2026 results (loss INR 0.01 crore)Routine
Q2 FY2026 (date not disclosed)AGM for FY2025 held; scrutinizer's report filedRoutine
Oct 2025Website updation filing; Reg. 74(5) certificate; trading-window closureFirst of two domain changes
17 Oct 2025Shares at INR 0.60; 52-week range INR 0.56–1.45 (Kotak)Share price near a multi-year low
5 Nov 2025Board meeting: Q2 FY2026 results; loss of INR 4.20 lakhRoutine
25 Dec 2025Shares at INR 0.60; one-year return of –52% (Kotak)Trough of the cycle
19 Jan 2026Board-meeting intimation (Reg. 29)Routine
2 Feb 2026Board meeting: Q3 FY2026 results (profit INR 1.00 lakh) plus Reg. 30 disclosureCoincides with CFO Rathod's exit
2 Feb 2026Dineshkumar Rathod ceased as Director (Finance)/CFOKMP change
17 Feb 2026Shares rose 15% intraday to INR 0.70 (Bajaj Finserv)Volatility typical of an illiquid micro-cap
15 Apr 2026Company Secretary resigned; new CS appointedKMP change
20 Apr 2026Shares at INR 0.70—
28 Apr 2026Board-meeting intimation for FY2026 resultsRoutine
5 May 2026Board approved audited FY2026 results; March 2026 quarter profit after tax of INR 6.20 lakh; FY2026 net profit INR 0.02 croreRoutine
19 May 2026Shares at INR 0.74—
Jul 2026Stock under BSE GSM and ASM surveillance (Trendlyne)Trading restrictions and margin requirements apply
27 Jul 2026Shares at INR 0.90; six-month gain of about 43% (IIFL)Speculative rally
3 Aug 2026Board meeting: Q1 FY2027 results; loss of INR 0.08 crore with zero incomeTreasury income did not recur
4 Sep 2026Shares at INR 0.86; market cap INR 5.68 crore; 52-week high INR 1.03—
17 Sep 2026Trading window closed from 1 Oct 2026 until 48 hours after the September-quarter resultsQ2 FY2027 results pending
24 Sep 2026AGM approved FY2026 accounts and appointed Albert Hines as WTD & CFO; scrutinizer's report filedNew finance lead
6 Oct 2026Reg. 74(5) certificate (SEBI Depositories Regulations)Routine
10 Oct 2026Website changed to www.amerisebiosciencesltd.barSecond domain change in about 12 months
19 Oct 2026Shares at INR 0.81 (–3.6% on the day); market cap INR 5.35 croreCurrent

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Sales held from INR 0 Mn in Jun-2023 to INR 0 Mn in Jun-2026.
Amradeep Industries Limited — Revenue by Segment
Series (INR Mn)Jun-2023Sep-2023Dec-2023Mar-2024Jun-2024Sep-2024Dec-2024Mar-2025Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026
Sales0000.40001.90.60.70.40.80
Expenses0.70.40.60.20.50.30.20.80.71.10.30.20.8
Net profit-0.7-0.4-0.60.2-0.5-0.3-0.21.1-0.1-0.40.10.6-0.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Screener.in – Amerise Biosciences Ltd (BSE 531681): financials FY2015–FY2026, quarterly results, shareholding, announcements, annual report index (screener.in)
  2. BSE filing, 01.11.2021 – ROC name approval (Amradeep Industries Ltd to Amerise Biosciences Ltd) (bseindia.com)
  3. BSE filing, 22.01.2024 – Q3 FY2024 unaudited results (CIN, "formerly Amradeep Industries") (bseindia.com)
  4. BSE – Annual Report 2009–10 (25th AGM; castor seeds; director Mahendra Ganatra) (bseindia.com)
  5. BSE – Annual Report / audit report March 2008 (bseindia.com)
  6. Kotak Neo – company background, FY2025 business status (kotakneo.com)
  7. Kotak Securities – price data and announcements, Oct and Dec 2025 (kotaksecurities.com)
  8. IIFL – price, market cap, returns, KMP titles (Aug–Sep 2026) (indiainfoline.com)
  9. Zerodha Markets – peers, net debt as of March 2026 (zerodha.com)
  10. Trendlyne – dividend history, GSM/ASM flags, board meeting dates (trendlyne.com)
  11. Tickertape – activity status and board-meeting history (tickertape.in)
  12. Emkay Global – BSE announcements feed 2026 (emkayglobal.com)
  13. Fyers – quarterly PAT news items (fyers.in)
  14. MarketScreener – Dineshkumar Rathod profile (au.marketscreener.com)
  15. Blinkx – board of directors listing (blinkx.in)
  16. Bajaj Finserv – shareholder names and company history (bajajfinserv.in)
  17. Bajaj Finserv Markets – SAST disclosures (Snehjeev Ventures & PACs) (bajajfinservmarkets.in)
  18. MarketsMojo (Motilal Oswal) – registered office, RTA, ISIN (marketsmojo.motilaloswal.com)
  19. StockEdge – shares outstanding, legacy website (stockedge.com)
  20. Equitymaster – peer comparison data (FY2023/FY2024) (equitymaster.com)
  21. Pocketful – corporate history timeline (pocketful.in)
  22. JM Financial – company information and address (jmfinancialservices.in)
  23. Zerodha (news aggregation from India Infoline and Business Standard) (stocks.zerodha.com)
  24. Amerise Pharmaceuticals Pvt Ltd website (private company) (amerisepharma.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.